Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Olaparib acts as an inhibitor of the enzyme poly ADP ribose polymerase (PARP), and is termed a PARP inhibitor. BRCA1/2 mutations may be genetically predisposed to development of some forms of cancer, and may be resistant to other forms of cancer treatment.

Where can I buy Lynparza?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience.

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Lynparza (olaparib) on prescription and Import License in Patient's Name only.

For Lynparza or olaparib price in India.
Please contact +91 9811747774 or neeraj@indianpharmanetwork.co.in
Lynparza (olaparib)

Get In Touch

Facilitator under Patient Assistance Programs In India

For Indian Patients, doctors and hospitals Lynparza (olaparib) can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

Tablets: 150 mg, 100 mg

ReadMore

FDA News Release

The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer.
Dated: APRIL 3, 2018

ReadMore